Stock Market News·2025-11-03 16:38Group 1: Acquisition Proposal - Novo Nordisk has submitted an unsolicited acquisition proposal for Metsera valued at up to $9 billion, challenging Metsera's existing agreement with Pfizer valued at up to $7.3 billion [2][9] - Metsera's board has determined Novo Nordisk's offer constitutes a "superior company proposal," triggering a four-business-day period for Pfizer to renegotiate its original deal [3][9] Group 2: Legal and Competitive Dynamics - Pfizer has accused Novo Nordisk of "reckless and unprecedented" behavior, alleging attempts to suppress competition and circumvent antitrust laws, and is prepared to pursue legal avenues [4][9] - Novo Nordisk has refuted Pfizer's accusations, asserting that Pfizer is "fundamentally wrong" about the competitive dynamics and expressing confidence that the transaction does not raise antitrust issues [5][9] Group 3: Market Context - The bidding war highlights intense competition in the obesity and metabolic disorder treatment market, projected to reach $150 billion by the early 2030s, with potential legal challenges that could reshape the pharmaceutical sector [5][9] Group 4: Other Market News - Wedbush has raised its price target for Amazon to $340 from $330, indicating continued confidence in Amazon's financial outlook and growth prospects [6][9]